A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)
NCT 05086692 Brief Summary This is a Phase 1/2, multi-center, open-label, dose-escalation…
Read more arrow_forwardNCT 05086692 Brief Summary This is a Phase 1/2, multi-center, open-label, dose-escalation…
Read more arrow_forwardNCT 05923008 Brief Summary This is a phase 1/2 multicenter, open-label, first-in-human…
Read more arrow_forwardNCT 05763004 Brief Summary The goal of this clinical trial is to…
Read more arrow_forwardNCT 06625593 Brief Summary The purpose of this study is to evaluate…
Read more arrow_forwardNCT 06422520 Brief Summary This is a first-in-human, Phase 1a/1b study to…
Read more arrow_forwardNCT 06914128 Brief Summary The study treatment, BAY 3713372, is under development…
Read more arrow_forwardNCT 05999994 Brief Summary The main purpose of the master is to…
Read more arrow_forwardACTRN 12623000108617 Brief Summary This study aims to assess a new cancer…
Read more arrow_forwardNCT 06170190 Brief Summary This is a multicentre, open-label, first-in-human, phase 1/2…
Read more arrow_forwardNCT 07016490 Brief Summary This study is an open-label phase I study…
Read more arrow_forwardNCT 05914116 Brief Summary This is a dose-escalation and dose-expansion Phase 1/2a…
Read more arrow_forwardACTRN 12622000993796 Brief Summary AXA-042 functions through a multi-cellular mechanism to re-engage…
Read more arrow_forwardNCT 06384352 Brief Summary This is a multicenter, open-label, Phase 1 study.…
Read more arrow_forwardACTRN 12623000307606 Brief Summary This study is investigating a new cancer treatment…
Read more arrow_forwardACTRN 12622001339741 Brief Summary This is a first in human study of…
Read more arrow_forwardNCT 06815575 Brief Summary This is a multi-centre, two-part, open-label, phase 1,…
Read more arrow_forwardNCT 05981703 Brief Summary This is an open-label, multicenter, and nonrandomized dose…
Read more arrow_forwardNCT 06929663 Brief Summary This is an first-in-human, Phase I clinical study…
Read more arrow_forwardNCT 05094336 Brief Summary The primary objective of Parts 1 and 2…
Read more arrow_forwardNCT 06669975 Brief Summary This is a Phase 1/2, multi-regional, multi-center, open-label,…
Read more arrow_forwardNCT 06130553 Brief Summary This is a first time in human (FTiH)…
Read more arrow_forwardNCT 06803680 Brief Summary The goal of this clinical trial is to…
Read more arrow_forwardNCT 05346484 Brief Summary This is an open-label, dose-escalation, multi-center phase I…
Read more arrow_forwardNCT 05279300 Brief Summary This is a first-in-human (FIH) study to evaluate…
Read more arrow_forwardNCT 05410145 Brief Summary This is a first-in-human (FIH), multicenter, open-label, dose-escalation,…
Read more arrow_forwardNCT 05985083 Brief Summary This is a first-in-human (FIH), open-label, multi-center, phase…
Read more arrow_forwardNCT 05384626 Brief Summary Phase 1/2, dose escalation and expansion study designed…
Read more arrow_forwardNCT 06063681 Brief Summary This is an open-label, dose-escalation, multi-center phase 1…
Read more arrow_forwardNCT 05205109 Brief Summary This is a study of ATG-037 Monotherapy and…
Read more arrow_forwardNCT 04913285 Brief Summary The purpose of this study is to evaluate…
Read more arrow_forwardNCT 06004245 Brief Summary This is a first-in-human, Phase I, open-label, multicenter,…
Read more arrow_forwardNCT 06004245 Brief Summary This is a first-in-human, Phase I, open-label, multicenter,…
Read more arrow_forwardNCT 06326411 Brief Summary This is a two-part Phase 1, open label,…
Read more arrow_forwardNCT 06710847 Brief Summary Solid tumours are abnormal lumps of tissue that…
Read more arrow_forwardNCT 06533059 Brief Summary The purpose of this study is to characterize…
Read more arrow_forwardNCT 06760819 Brief Summary Researchers are looking for a better way to…
Read more arrow_forwardNCT 06597721 Brief Summary Adcendo ApS is conducting a phase 1 study…
Read more arrow_forwardNCT 05906862 Brief Summary This first-in-human study will evaluate the Maximum Tolerated…
Read more arrow_forwardNCT 03175224 Brief Summary To assess: efficacy of APL-101 as monotherapy for…
Read more arrow_forwardNCT 05807035 Brief Summary Phase 1 trial to evaluate the feasibility of…
Read more arrow_forwardNCT 06219941 Brief Summary The purpose of this study is to assess…
Read more arrow_forward